Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

BACKGROUND: The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance. Dolutegravir (DTG, S/GSK1349572), a second-generation drug that ove...

全面介紹

Na minha lista:
書目詳細資料
發表在:AIDS Res Ther
Main Authors: Jiang, Junjun, Xu, Xi, Guo, Wenqin, Su, Jinming, Huang, Jiegang, Liang, Bingyu, Chen, Hui, Zang, Ning, Liao, Yanyan, Ye, Li, Liang, Hao
格式: Artigo
語言:Inglês
出版: BioMed Central 2016
主題:
Review
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016965/
https://ncbi.nlm.nih.gov/pubmed/27617024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-016-0115-x
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍